158 related articles for article (PubMed ID: 36914043)
1. Quantitative analysis of ethanolamine plasmalogen species in red blood cells using liquid chromatography tandem mass spectrometry for diagnosing peroxisome biogenesis disorders.
De Biase I; Yuzyuk T; Cui W; Zuromski LM; Moser AB; Braverman NE
Clin Chim Acta; 2023 Mar; 542():117295. PubMed ID: 36914043
[TBL] [Abstract][Full Text] [Related]
2. Oral administration of a synthetic vinyl-ether plasmalogen normalizes open field activity in a mouse model of rhizomelic chondrodysplasia punctata.
Fallatah W; Smith T; Cui W; Jayasinghe D; Di Pietro E; Ritchie SA; Braverman N
Dis Model Mech; 2020 Jan; 13(1):. PubMed ID: 31862688
[TBL] [Abstract][Full Text] [Related]
3. Homeostasis of phospholipids - The level of phosphatidylethanolamine tightly adapts to changes in ethanolamine plasmalogens.
Dorninger F; Brodde A; Braverman NE; Moser AB; Just WW; Forss-Petter S; Brügger B; Berger J
Biochim Biophys Acta; 2015 Feb; 1851(2):117-28. PubMed ID: 25463479
[TBL] [Abstract][Full Text] [Related]
4. A Pex7 hypomorphic mouse model for plasmalogen deficiency affecting the lens and skeleton.
Braverman N; Zhang R; Chen L; Nimmo G; Scheper S; Tran T; Chaudhury R; Moser A; Steinberg S
Mol Genet Metab; 2010 Apr; 99(4):408-16. PubMed ID: 20060764
[TBL] [Abstract][Full Text] [Related]
5. The importance of ether-phospholipids: a view from the perspective of mouse models.
da Silva TF; Sousa VF; Malheiro AR; Brites P
Biochim Biophys Acta; 2012 Sep; 1822(9):1501-8. PubMed ID: 22659211
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo plasmalogen replacement evaluations in rhizomelic chrondrodysplasia punctata and Pelizaeus-Merzbacher disease using PPI-1011, an ether lipid plasmalogen precursor.
Wood PL; Khan MA; Smith T; Ehrmantraut G; Jin W; Cui W; Braverman NE; Goodenowe DB
Lipids Health Dis; 2011 Oct; 10():182. PubMed ID: 22008564
[TBL] [Abstract][Full Text] [Related]
7. MRI of the brain and cervical spinal cord in rhizomelic chondrodysplasia punctata.
Bams-Mengerink AM; Majoie CB; Duran M; Wanders RJ; Van Hove J; Scheurer CD; Barth PG; Poll-The BT
Neurology; 2006 Mar; 66(6):798-803; discussion 789. PubMed ID: 16567694
[TBL] [Abstract][Full Text] [Related]
8. Mild reduction of plasmalogens causes rhizomelic chondrodysplasia punctata: functional characterization of a novel mutation.
Noguchi M; Honsho M; Abe Y; Toyama R; Niwa H; Sato Y; Ghaedi K; Rahmanifar A; Shafeghati Y; Fujiki Y
J Hum Genet; 2014 Jul; 59(7):387-92. PubMed ID: 24849933
[TBL] [Abstract][Full Text] [Related]
9. A new test method for biochemical analysis of plasmalogens in dried blood spots and erythrocytes from patients with peroxisomal disorders.
Wegwerth PJ; White AL; Stoway SD; Loken PR; Oglesbee D; Matern D; Tortorelli S; Raymond KM; Braverman NE; Gavrilov DK
J Inherit Metab Dis; 2023 Nov; 46(6):1159-1169. PubMed ID: 37747296
[TBL] [Abstract][Full Text] [Related]
10. Plasmalogens and fatty alcohols in rhizomelic chondrodysplasia punctata and Sjögren-Larsson syndrome.
Malheiro AR; da Silva TF; Brites P
J Inherit Metab Dis; 2015 Jan; 38(1):111-21. PubMed ID: 25432520
[TBL] [Abstract][Full Text] [Related]
11. Rhizomelic chondrodysplasia punctata and cardiac pathology.
Huffnagel IC; Clur SA; Bams-Mengerink AM; Blom NA; Wanders RJ; Waterham HR; Poll-The BT
J Med Genet; 2013 Jul; 50(7):419-24. PubMed ID: 23572185
[TBL] [Abstract][Full Text] [Related]
12. Expanding the genotypic and phenotypic landscapes of rhizomelic chondrodysplasia punctata type 3 (RCDP3) with two novel families, and a review of the literature.
İli EG; Gezdirici A; Di Pietro E; Yergeau C; Braverman N
Am J Med Genet A; 2022 Nov; 188(11):3229-3235. PubMed ID: 35986576
[TBL] [Abstract][Full Text] [Related]
13. A
Fallatah W; Cui W; Di Pietro E; Carter GT; Pounder B; Dorninger F; Pifl C; Moser AB; Berger J; Braverman NE
Front Cell Dev Biol; 2022; 10():886316. PubMed ID: 35898397
[TBL] [Abstract][Full Text] [Related]
14. Growth charts for individuals with rhizomelic chondrodysplasia punctata.
Duker AL; Niiler T; Eldridge G; Brereton NH; Braverman NE; Bober MB
Am J Med Genet A; 2017 Jan; 173(1):108-113. PubMed ID: 27616591
[TBL] [Abstract][Full Text] [Related]
15. Functions of plasmalogen lipids in health and disease.
Braverman NE; Moser AB
Biochim Biophys Acta; 2012 Sep; 1822(9):1442-52. PubMed ID: 22627108
[TBL] [Abstract][Full Text] [Related]
16. Leukodystrophy caused by plasmalogen deficiency rescued by glyceryl 1-myristyl ether treatment.
Malheiro AR; Correia B; Ferreira da Silva T; Bessa-Neto D; Van Veldhoven PP; Brites P
Brain Pathol; 2019 Sep; 29(5):622-639. PubMed ID: 30667116
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome biogenesis disorders.
Steinberg SJ; Dodt G; Raymond GV; Braverman NE; Moser AB; Moser HW
Biochim Biophys Acta; 2006 Dec; 1763(12):1733-48. PubMed ID: 17055079
[TBL] [Abstract][Full Text] [Related]
18. Functional characterization of novel mutations in GNPAT and AGPS, causing rhizomelic chondrodysplasia punctata (RCDP) types 2 and 3.
Itzkovitz B; Jiralerspong S; Nimmo G; Loscalzo M; Horovitz DD; Snowden A; Moser A; Steinberg S; Braverman N
Hum Mutat; 2012 Jan; 33(1):189-97. PubMed ID: 21990100
[TBL] [Abstract][Full Text] [Related]
19. Tricky Isomers-The Evolution of Analytical Strategies to Characterize Plasmalogens and Plasmanyl Ether Lipids.
Koch J; Watschinger K; Werner ER; Keller MA
Front Cell Dev Biol; 2022; 10():864716. PubMed ID: 35573699
[TBL] [Abstract][Full Text] [Related]
20. Rhizomelic chondrodysplasia punctata, a peroxisomal biogenesis disorder caused by defects in Pex7p, a peroxisomal protein import receptor: a minireview.
Purdue PE; Skoneczny M; Yang X; Zhang JW; Lazarow PB
Neurochem Res; 1999 Apr; 24(4):581-6. PubMed ID: 10227689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
